Fundraising Fox
/Companies
Sign in

Aethlon Medical

NASDAQ: AEMD

San Diego, US · Nevada corporation

Find your way into Aethlon Medical

95 people in our graph can introduce you to the Aethlon Medical team.

Sign up to see every warm intro you have to Aethlon Medical

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Aethlon Medical team. We find them
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes you can't see from your own inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Aethlon Medical develops the Hemopurifier, a clinical-stage extracorporeal device that uses lectin-based technology to remove extracellular vesicles and enveloped viruses from blood plasma, with current clinical programs targeting patients with advanced cancer resistant to immunotherapy and potential applications in life-threatening viral infections. The company is advancing safety and feasibility trials in Australia for cancer treatment and maintains regulatory pathways for viral indications while exploring additional disease applications through preclinical research.

Biotech

Founders & leadership

RH
Richard H. TullisFounder
JB
James B. FrakesExecutive
RS
Rodney S. KenleyExecutive
JJ
James JoycePresident/CEOformer
SPSteven P. LaRosa
Steven P. LaRosaChief Medical OfficerSteven P. LaRosa is Chief Medical Officer of Aethlon Medical and holds a medical degree from Boston University School of Medicine with board certifications in internal medicine and infectious disease. He brings 28 years of clinical development experience in biotechnology and pharma across infectious diseases, oncology, and medical devices, including 5.5 years as CMO at a NASDAQ-traded biotech company and 19 years of infectious disease clinical practice at academic medical centers including Cleveland Clinic and Massachusetts General Hospital.
RH
RICHARD H. TULLIS, PhDNamed on SEC filing

Board

CS
Chetan S. Shah, M.D.Board director
EG
Edward G. BroennimanBoard director
NG
Nicolas GikakisBoard director
AR
Angela RossettiBoard director
FS
Franklyn S. Barry, Jr.Board director
CS
CHETAN SHAH, MDBoard director

Reported raises · per SEC filings

Form D private placements

$20.2M disclosed across 10 rounds · 2011–2025

▶$2.2MraisedDec 2025 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Chetan S. Shah, M.D.Director
  • James B. FrakesExecutive Officer, Director
  • Edward G. BroennimanDirector
  • Nicolas GikakisDirector
  • Angela RossettiDirector
Offering amount
$2.2M
Amount sold
$2.2M
Sales commissions
$214.5K
First sale
Dec 2025
Incorporated
Corporation, Nevada
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2.7MraisedJan 2020 · 7 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • TIMOTHY C. RODELLExecutive Officer, Director
  • SABRINA MARTUCCI JOHNSONDirector
  • EDWARD G. BROENNIMANDirector
  • CHARLES J. FISHERDirector
  • CHETAN S. SHAHDirector
  • JAMES B. FRAKESExecutive Officer
  • GUY CIPRIANIDirector
Offering amount
$2.7M
Amount sold
$2.7M
Sales commissions
$226.2K
Placement agents
H.C. Wainwright & Co., LLC
First sale
Jan 2020
Incorporated
Corporation, Nevada
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$6MraisedJul 2015 · 19 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • RODNEY S. KENLEYExecutive Officer, Director
  • FRANKLYN S. BARRY, JR.Director
  • JAMES B. FRAKESExecutive Officer
  • EDWARD G. BROENNIMANDirector
  • RICHARD H. TULLIS, PhDExecutive Officer
  • JAMES A. JOYCEExecutive Officer, Director
  • CHETAN SHAH, MDDirector
Offering amount
$6M
Amount sold
$6M
Sales commissions
$360.5K
Placement agents
ROTH Capital Partners, LLC
First sale
Jun 2015
Incorporated
Corporation, Nevada
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$3.3MraisedDec 2014 · 4 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • James B. FrakesExecutive Officer
  • Rodney S. KenleyExecutive Officer, Director
  • Franklyn S. Barry, Jr.Director
  • James A. JoyceExecutive Officer, Director
  • Edward G. BroennimanDirector
  • Richard H. Tullis, PhDExecutive Officer, Director
  • Chetan Shah, MDDirector
Offering amount
$3.3M
Amount sold
$3.3M
Sales commissions
$256K
Placement agents
ROTH Capital Partners, LLC
First sale
Dec 2014
Incorporated
Corporation, Nevada
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$527.8KraisedNov 2014 · 2 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Rodney S. KenleyExecutive Officer, Director
  • Franklyn S. Barry, Jr.Director
  • Richard H. Tulls, PhDExecutive Officer, Director
  • James B. FrakesExecutive Officer
  • Chetan Shah, MDDirector
  • Edward G. BroennimanDirector
  • James A. JoyceExecutive Officer, Director
Offering amount
$527.8K
Amount sold
$527.8K
First sale
Nov 2014
Incorporated
Corporation, Nevada
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$837.7KraisedNov 2014 · 3 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • JAMES A. JOYCEExecutive Officer, Director
  • RODNEY S. KENLEYExecutive Officer, Director
  • FRANKLYN S. BARRY, JR.Director
  • RICHARD H. TULLIS, PhDExecutive Officer, Director
  • CHETAN SHAH, MDDirector
  • JAMES B. FRAKESExecutive Officer
  • EDWARD G. BROENNIMANDirector
Offering amount
$837.7K
Amount sold
$837.7K
First sale
Oct 2014
Incorporated
Corporation, Nevada
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$838.7KraisedNov 2014 · 9 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • JAMES B. FRAKESExecutive Officer
  • FRANKLYN S. BARRY, JR.Director
  • EDWARD G. BROENNIMANDirector
  • RICHARD H. TULLIS, PhDExecutive Officer, Director
  • JAMES A. JOYCEExecutive Officer, Director
  • RODNEY S. KENLEYExecutive Officer, Director
  • CHETAN SHAH, MDDirector
Offering amount
$838.7K
Amount sold
$838.7K
First sale
Jul 2014
Incorporated
Corporation, Nevada
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$913.5KraisedNov 2014 · 14 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • EDWARD G. BROENNIMANDirector
  • RICHARD H. TULLIS, PhDExecutive Officer, Director
  • RODNEY S. KENLEYExecutive Officer, Director
  • CHETAN SHAH, MDDirector
  • JAMES A. JOYCEExecutive Officer, Director
  • FRANKLYN S. BARRY, JR.Director
  • JAMES B. FRAKESExecutive Officer
Offering amount
$913.5K
Amount sold
$913.5K
Minimum investment
$10K
First sale
May 2014
Incorporated
Corporation, Nevada
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 6

TradingViewTradingView is a charting platform and social network used by over 100 million traders and investors worldwide to analyze and trade across global financial markets. The platform provides tools for technical analysis, market data, and community collaboration for retail and institutional traders.
RobinhoodRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
NasdaqNasdaq operates a technology infrastructure platform for financial markets across three business segments: Capital Access Platforms (which includes listing services, indices, and analytics tools), Financial Technology (comprising compliance, regulatory, and capital markets software), and Market Services (equities and derivatives trading operations). The company serves financial institutions, listed companies, investment managers, and regulatory agencies globally.
Seeking AlphaSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
StockTwitsStocktwits operates an online community platform where investors and traders share ideas, analysis, and trade discussions organized around stock tickers. The page presented is its community guidelines rather than a product description.
PublicPublic is a trading platform that allows users to buy and sell cryptocurrencies including Bitcoin, Ethereum, and memecoins through accounts managed by Zero Hash LLC, a New York State-licensed virtual currency business.

Companies working in the same space as Aethlon Medical.

Non-dilutive funding · 3 SBIR/STTR awards

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase II2019$1.9M
National Institutes of Health (NIH)National Institutes of HealthPhase I2018$298.4K
National Institutes of Health (NIH)National Institutes of HealthPhase I2017$299.3K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

Frequently asked questions

What does Aethlon Medical do?
Aethlon Medical develops the Hemopurifier, a clinical-stage extracorporeal device that uses lectin-based technology to remove extracellular vesicles and enveloped viruses from blood plasma, with current clinical programs targeting patients with advanced cancer resistant to immunotherapy and potential applications in life-threatening viral infections. The company is advancing safety and feasibility trials in Australia for cancer treatment and maintains regulatory pathways for viral indications while exploring additional disease applications through preclinical research.
Who founded Aethlon Medical?
Aethlon Medical was founded by Richard H. Tullis.
How much funding has Aethlon Medical raised?
Aethlon Medical has disclosed $20.2M raised across 10 rounds.
Where is Aethlon Medical headquartered?
Aethlon Medical is headquartered in San Diego, US.